Navigation Links
Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Date:3/10/2008

SOUTH SAN FRANCISCO, Calif., March 10 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics, today announced positive interim data from the company's ongoing Phase 2 clinical trial of its lead product candidate, SNS-595, in platinum-resistant ovarian cancer patients.

In this Phase 2 clinical trial, single agent SNS-595 has demonstrated disease control (defined as stable disease, partial response or complete response) in 31 of 35 patients evaluable for best response using GOG-RECIST criteria. Of these 31 patients, one patient had a complete response, four patients had partial responses (two unconfirmed) and 26 patients had a best response of stable disease. All patients enrolled in the trial have previously failed treatment with platinum-containing regimens, and fourteen of the 35 patients have also failed prior treatment with doxorubicin HCl liposome injection (Doxil(R)). Both platinum-resistant and Doxil-resistant patients in the Phase 2 clinical trial have responded to SNS-595 therapy.

"Recurrence rates among ovarian cancer patients remain high, and the majority of refractory patients are resistant to platinum-based therapies. Based on these interim data, SNS-595 appears to be a promising, active agent in a difficult-to-treat ovarian cancer patient population," said William P. McGuire, M.D., Medical Director of the Harry and Jeanette Weinberg Cancer Institute at Franklin Square, and a lead investigator for the Phase 2 trial.

Among forty-five patients with sufficient follow-up to yield safety data, SNS-595 was generally well tolerated at a dose level of 48mg/m2
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
4. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
5. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
6. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
7. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
8. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
9. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
10. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
11. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
(Date:12/24/2014)... 2014  Diplomat Pharmacy, Inc. (NYSE: DPLO ... to announce Jennifer Hagerman , Pharm.D., AE-C, senior ... office as the president of the Michigan Pharmacists Association ... take place Feb. 28, 2015, at the MPA Annual ... Renaissance Center in Detroit, Michigan . ...
(Date:12/24/2014)... NEW YORK and LONDON ... in global orthopedic industry are expected to grow at ... consumption in terms of value and volume. Hip, knee ... the developed world while in emerging economies they have ... failure rates are challenging the use of composites. Non-metallic ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... 15 Inverness Medical Innovations, Inc. (NYSE: IMA ... their health at home through the merger of rapid diagnostics and ... Alere Inc., after shareholders approved the name change at its Annual ... Company also announced that it expects its NYSE stock symbol to ...
... LAKE FOREST, Ill. , July 15 ... on the healthcare industry, announced today the closing of its third ... second captive subordinated debt fund of $200 million ("Capital ... million in March 2002 and its second equity ...
Cached Medicine Technology:RoundTable Healthcare Partners Closes Two Funds 2RoundTable Healthcare Partners Closes Two Funds 3
(Date:12/26/2014)... 2014 Plugin and template developers from ... Plugin for Final Cut Pro X. , “TransPack Volume 5 ... to pull off an industry professional look” Said Christina Austin, ... on TransPack Volume 5, a new level of professionalism will ... of over 50 Final Cut Pro X transitions featuring organic ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the Best ... 2014. The awards program, created in 2000, is one ... the country. The program is a public/private partnership between ... Economic Development, the Pennsylvania State Council of the Society ... Journal. , Charlie Wilson, Vice President of ...
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... 2014 The report “Nintedanib (Colorectal ... focuses on the current treatment landscape, unmet needs, ... cancer market. Stivarga is a drug which is ... cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an ... refractory CRC in the US, Europe, and Japan. ...
(Date:12/25/2014)... 2014 “Every three months the trends for ... sweetheart evening dress will be one of the hottest styles ... Yunx.co.uk says. Today, the company releases 26 A-line sweetheart evening ... 80% off. , “We are trying our best to ... our latest designs. Along with affordable prices, we provide discounted ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... been a considerable increase in the number of repeat cesarean ... 8-year study conducted between 1996 and 2003 survey has further ... unexplained reasons. ,According to National statistics, there has ... in women who have had a cesarean. Concomitantly, there has ...
... first step to retaining a good memory as we age is ... that they could control their memory are more likely to use ... ,The researchers analyzed the link between a sense of control ... and 83 years. The study participants were required to recall a ...
... pollution could be responsible for increase in cardiac and ... the recent issue of JAMA. , The ... disorders have been highlighted by numerous environment based studies. ... health is being perceived as a major public health ...
... of an association between aluminum salts contained in deodorants ... like cadmium and aluminum are believed to exert estrogen-like ... ,Under laboratory conditions, these salts have even ... cell lines, highlighting the carcinogenic potential of such compounds, ...
... increased over the last 10 years, a survey has found. ... ,A South Australian survey conducted between 1990 and 2003 ... from 7.3 percent in 1990 to 14.6 percent in 2003. ... people aged 55 and above. Overall the prevalence rate rose ...
... University of Illinois at Urbana-Champaign developed an innovative ... new drug and agricultural materials and delivery vehicles. ... engineering, chemistry and physics said that it was ... biofunctional capsules could be used in drug delivery, ...
Cached Medicine News:Health News:Want To Retain Your Memory? Believe That You Can Do So! 2Health News:Air Pollution Exposure Increases Risk Of Heart And Respiratory Disease 2Health News:Aluminum Salts In Underarm Deodorants Increase Risk Of Breast Cancer 2Health News:Medical Boon in the Form of a Biofriendly Capsule 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: